Table 1 Characteristics of study sample at baseline, according to treatment allocationâ€
| Â | Placebo n = 21 | 50,000 n = 22 | 100,000 n = 22 | Missing Cases (Placebo/50,000/100,000) |
|---|---|---|---|---|
Age in years | 78.5 (10.3) | 82.9 (8.7) * | 73.9(12.4) * | 1/0/0 |
   Male (SD) | 77.9 (8.4) | 77.9 (11.2) | 69.5 (12.9) |  |
   Female (SD) | 78.8 (11.5) | 85.2 (6.4) | 81.7 (6.6) |  |
Gender | Â | Â | Â | 1/0/0 |
   Male (%) | 7 (35) | 7 (32) | 14 (64) |  |
   Female (%) | 13 (65) | 15 (68) | 8 (36) |  |
Height, cm | 163.8 (11.4) | 162.9 (10.1) | 169.7 (12.6) | 2/3/2 |
   Male (SD) | 174.8 (10.2) | 173.5 (4.7) | 175.0 (10.3) |  |
   Female (SD) | 158.7 (7.9) | 156.7 (6.3) | 158.2 (7.3) |  |
Weight, kg | 70.6 (25.4) | 64.8 (18.1) | 72.1 (15.8) | 2/2/2 |
   Male (SD) | 89.1 (30.3) | 79.4 (12.7) | 76.1 (10.8) |  |
   Female (SD) | 62.1(18.4) | 57.0 (15.8) | 64.6 (21.4) |  |
Prior Smoking (%) | 9 (50) | 7 (39) | 11 (58) | 3/4/3 |
Previous fracture documented (%) | 3 (15) | 5 (23) | 6 (27) | 1/0/0 |
Prior vitamin D use (%) | 4 (20) | 1 (4.5) | 4 (18) | 1/0/0 |
Prior calcium use (%) | 5 (25) | 2 (9) | 4 (18) | 1/0/0 |
Number of medications at admission (SD) | 6.2 (4.6) | 6.0 (3.8) | 5.0 (4.4) | 1/0/0 |
Charlson index (SD) | 1.30 (1.13) | 0.82 (1.18) | 0.55 (0.80) | 2/0/0 |
Ambulatory without aids prior to admission (%) | 8 (44) | 13 (72) | 13 (68) | 3/4/3 |
Total calcium, mmol/L (SD) | 2.10 (0.14) | 2.12 (0.11) | 2.08 (0.14) | 1/1/0 |
Hb, g/L (SD) | 108.6 (15.2) | 102.2 (14.3) | 107.9 (17.4) | 1/0/0 |
Albumin, g/L (SD) | 34.1 (6.0) | 33.0 (5.8) | 32.4 (5.4) | 1/5/4 |
Creatinine, umol/L (SD) | 73.7 (37.0) | 70.5 (23.8) | 77.4 (26.1) | 1/0/0 |
Phosphate, mmol/L (SD) | 0.94 (0.27) | 0.86 (0.22) | 0.97 (0.24) | 1/0/0 |
Alkaline phosphatase, U/L (SD) | 98.6 (37.8) | 78.7 (26.2) | 79.4 (51.1) | 1/0/0 |
Parathyroid Hormone (PTH), pmol/L (SD) | 4.20 (2.12) | 5.35 (3.01) | 5.10 (3.91) | 1/0/0 |